NCT02223598View on ClinicalTrials.gov

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 25, 2014

Primary Completion Date

July 26, 2017

Study Completion Date

July 26, 2017

Conditions
Lymphoid Hematological MalignanciesRelapsed and Refractory Multiple Myeloma
Interventions
DRUG

CB-5083

DRUG

Dexamethasone

Trial Locations (8)

20817

RCCA MD, Bethesda

30322

Emory University, Atlanta

63110

Washington University, St Louis

91010

City of Hope National Medical Center, Duarte

94143

University of California, San Francisco, San Francisco

07601

Hackensack University Medical Center, Hackensack

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H4A 3J1

Cedars Cancer Centre, McGill University Health Centre, Montreal

Sponsors
All Listed Sponsors
lead

Cleave Biosciences, Inc.

INDUSTRY